Sean F. Moran Acquires 2,500 Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) CFO Sean F. Moran acquired 2,500 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were bought at an average cost of $5.91 per share, for a total transaction of $14,775.00. Following the completion of the acquisition, the chief financial officer now directly owns 339,410 shares of the company’s stock, valued at approximately $2,005,913.10. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) traded up 3.4171% on Friday, hitting $6.0499. 309,167 shares of the stock were exchanged. Corbus Pharmaceuticals Holdings, Inc. has a 1-year low of $2.95 and a 1-year high of $10.78. The company has a 50-day moving average price of $6.27 and a 200 day moving average price of $7.09. The company’s market capitalization is $303.83 million.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. The business had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.50 million. Corbus Pharmaceuticals Holdings had a negative net margin of 1,001.77% and a negative return on equity of 126.20%. Analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post ($0.73) EPS for the current fiscal year.
CRBP has been the topic of a number of recent research reports. Noble Financial reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a report on Saturday, May 6th. Cantor Fitzgerald set a $24.00 price objective on Corbus Pharmaceuticals Holdings and gave the company a “buy” rating in a report on Tuesday, May 9th. Finally, BidaskClub raised Corbus Pharmaceuticals Holdings from a “sell” rating to a “hold” rating in a report on Saturday, July 8th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Corbus Pharmaceuticals Holdings has an average rating of “Buy” and an average price target of $20.50.
Several hedge funds have recently bought and sold shares of CRBP. IPG Investment Advisors LLC purchased a new stake in Corbus Pharmaceuticals Holdings during the first quarter valued at about $109,000. Quantbot Technologies LP purchased a new stake in Corbus Pharmaceuticals Holdings during the first quarter valued at about $114,000. SG Americas Securities LLC purchased a new stake in Corbus Pharmaceuticals Holdings during the first quarter valued at about $148,000. Credit Suisse AG purchased a new stake in Corbus Pharmaceuticals Holdings during the first quarter valued at about $157,000. Finally, Evanson Asset Management LLC raised its stake in Corbus Pharmaceuticals Holdings by 1.8% in the first quarter. Evanson Asset Management LLC now owns 20,360 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 360 shares in the last quarter. Institutional investors and hedge funds own 28.12% of the company’s stock.
Corbus Pharmaceuticals Holdings Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.